John Marshall, MD, discussed zolbetuximab, which the FDA recently approved for patients with CLDN18.2–positive locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.

Surgery followed by platinum-based chemotherapy may provide the most benefit for patients with ovarian cancer, according to a medical oncologist.

The FDA set a Prescription Drug User Fee act date in the second quarter of 2025 for durvalumab plus chemotherapy in muscle-invasive bladder cancer.

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.

The launch of this pazopanib tablet formulation for patients with RCC or sarcoma is anticipated in the fourth quarter of 2025.

Nemvaleukin with and without pembrolizumab yielded promising anti-tumor activity and was well tolerated in patients with advanced solid tumors.

The FDA is expected to decide on approving glofitamab in relapsed or refractory diffuse large B-cell lymphoma by July 20, 2025.

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.

Results from the phase 3 ADRIATIC trial led to the approval of durvalumab in limited-stage SCLC.

The rare nature of pancreatic cancer makes identifying it difficult, but progress towards earlier identification is being made, according to Brian M. Wolpin, MD, MPH.

Zenocutuzumab is now approved for patients with NRG1 fusion-positive NSCLC or pancreatic adenocarcinoma.

For patients with EGFR-mutated non–small cell lung cancer, sacituzumab tirumotecan was given the breakthrough drug designation by the FDA.

Neil M. Iyengar, MD, highlights the biggest advances in oncology, and where he expects the field to move next.

Tumor treating fields with chemotherapy improved overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma.

Identifying inefficiencies in the health care system, such as excessive regulations, highlights its impact on the oncology-based audience.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

Risk factors and biomarker testing in conjunction with cancer staging may better identify ideal treatment for endometrial cancer than cancer staging alone.

The European Commission has approved ribociclib plus an aromatase inhibitor for patients with early breast cancer.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab.

Shubham Pant, MD, MBBS, highlights how pan-RAS inhibitors, RAS-directed vaccines, and biomarker testing can improve outcomes in pancreatic cancer.

Treatment with vorasidenib also confers better seizure control than placebo in the phase 3 INDIGO study.

ASTRO assembled a task force to create a guideline for the administration of palliative external beam radiation therapy for patients with symptomatic bone metastases.

The European Commission has approved tislelizumab plus chemotherapy as treatment for patients with esophageal and gastric or GEJ cancer.

Despite gaps in biomarker testing accessibility, the lung cancer survival rate has improved by 26% over the last 5 years.